Medication info

Sitagliptin and Metformin Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›858.5mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200615 · Approved 2022.02.08 · Insurance code 653405200

Summary

Main use
Improvement of glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin treatment: For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's existing metformin dose. Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients Who Must Not Receive This Drug).

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medicine is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. Patients starting diabetes medication treatment for the first time can use this medicine alone, and it is helpful even when blood sugar control is difficult with monotherapy using either Metformin or Sitagliptin. Additionally, it can be co-administered with Metformin and sulfonylureas, or with thiazolidinediones to improve blood sugar. In cases where insulin and Metformin combination therapy are insufficient, this medicine can be used to expect better blood sugar control. Thus, this medicine is used to support blood sugar control at various stages of treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin treatment: For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's existing metformin dose. Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients Who Must Not Receive This Drug).

Precautions

This medicine contains Sitagliptin and Metformin hydrochloride, and is primarily used for the treatment of type 2 diabetes. During the use of this medicine, severe allergic reactions may occur, so if symptoms such as skin rash, hives, or difficulty breathing appear, discontinue use immediately and consult a doctor. Serious inflammation of the pancreas, known as pancreatitis, may occur. If severe abdominal pain, nausea, or vomiting arises, notify medical personnel immediately. This medicine is not to be administered to patients with severely impaired kidney function or those with serious infections, dehydration, heart failure, or acute myocardial infarction. Particularly, before and after examinations that use contrast agents, the use of this medicine should be discontinued and can be resumed only after kidney function has been confirmed to be normal. It is safe not to use this medicine in women who are pregnant or may become pregnant, and in breastfeeding mothers. This medicine can cause hypoglycemia, so caution should be taken during irregular meals or excessive exercise. Increased vigilance for hypoglycemic symptoms is required when taken with other diabetes medications like insulin or sulfonylureas. A rare but very dangerous metabolic abnormality called lactic acidosis may occur; if sudden muscle pain, difficulty breathing, weakness, or abdominal pain arises, immediate hospital attention is necessary. Additionally, this medicine is not recommended for patients with liver dysfunction or those who engage in excessive alcohol consumption. Elderly patients are more likely to have reduced kidney function; thus, it is necessary to regularly check kidney function while taking this medicine, and dosage adjustments may be needed. Before surgery, the use of this medicine should be discontinued for a certain period, and can be resumed only after confirming normal kidney function post-surgery. While taking this medication, regular blood tests should be performed to monitor kidney function and hematological values, and caution is needed as vitamin B12 deficiency may occur. There may be interactions with other medications taken in conjunction with this medicine, so if there are medications currently in use, it is essential to inform a doctor or pharmacist. In case of overdose, seek immediate medical treatment, as drug removal may be possible through dialysis. While taking this medicine, regular blood glucose monitoring and health status checks should be performed to ensure safe treatment.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in an airtight container, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medicine's effectiveness and ensures safe use.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.